|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00039923 |
Purpose
This study will examine blood cells of patients with paroxysmal nocturnal hemoglobinuria (PNH) after they receive a blood transfusion to determine if certain proteins (GPI-linked proteins) in the transfused blood transfer to the patient's blood cells. GPI-linked proteins, which are normally present on red cells and regulate red cell survival, are absent in patients with PNH. Their lack is believed to account for the premature destruction of red blood cells in these patients, resulting in a low hemoglobin and hematocrit. Patients may experience fatigue, flank pain and other symptoms, requiring treatment with blood transfusion.
Patients with PNH 18 years of age or older with group A1 blood who require at least three units of red cells and who have not been transfused with group O blood within the last 3 months may be eligible for this study.
Participants will come to the NIH Clinical Center for the following procedures:
Blood samples of 3 teaspoons each will be drawn 1 day, 1 week, and 3 weeks after the transfusion. These samples may be collected by the patient's doctor locally and sent to NIH by mail.
If it is found that GPI-linked proteins transfer to the patient's cells, the study will also examine how long the proteins remain attached and will assess whether the proteins are functional and prevent cell destruction.
| Condition |
|---|
|
Paroxysmal Hemoglobinuria |
| Study Type: | Observational |
| Official Title: | A Pilot Study to Determine if Transfer of Gpi-Linked Proteins Occurs Following Transfusion of Red Cells to Patients With Paroxysmal Nocturnal Hemoglobinuria |
| Estimated Enrollment: | 7 |
| Study Start Date: | June 2002 |
| Estimated Study Completion Date: | June 2005 |
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal bone marrow disorder, resulting from an acquired, somatic X-linked mutation of the PIG-A gene in an hematopoietic stem cell. Absence of PIG-A function in a cell prevents synthesis of the glycosylphosphatidylinositol (GPI) moiety, which anchors many different types of proteins to the cell membrane. Intravascular red cell destruction, the hallmark of the disorder, is caused by susceptibility of the abnormal erythrocyte to complement-mediated lysis; this sensitivity is due to lack of CD59, a potent inhibitor of the late components of complement and reactive lysis. In vitro studies from this laboratory have demonstrated transfer of GPI-linked proteins, CD55 and CD59, from normal to deficient cells and transfer is associated with resistance to hemolysis. Patients with PNH frequently require transfusion as their standard care. In addition, patients with all blood groups requiring transfusion will often receive compatible group O blood. Group O blood is prevalent in blood bank inventories; and red cell survival after transfusion is equal to that after transfusion of "in group" blood. The purpose of this study is to examine protein transfer of GPI-linked proteins from transfused cells to deficient cells obtained from patients with PNH. Patients with group A(1) blood will receive compatible group O blood so that donor and recipient blood cells can be discriminated. Flow cytometric studies will be performed subsequently to determine if transfer of GPI-linked protein to patients' cells has occurred.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA
The following must be met before the subject may be enrolled:
PNH patients with group A(1) blood who require at least three units of red cells as judged by their primary care physician; criteria for transfusion would include hemoglobin below 7.5 g/dl or symptoms related to anemia (impaired exercise tolerance, angina, shortness of breath) that warrant therapy.
A PNH clone of greater than 40% and not have been transfused with group O blood for at least three months previously.
Eighteen years of age or older.
Karnofsky performance status of 60% or better.
Adequate organ function as defined by serum creatinine less than 2.0 mg/dl.
Able to comprehend and willing to sign an informed consent.
EXCLUSION CRITERIA
Any one of the following eliminates a subject from participating:
Evidence of uncontrolled infection.
Known alloimmunization to red cell antigens.
Treatment with investigational agent or hematopoietic growth factors within 4 weeks of study entry.
Psychiatric, addictive or any disorder that compromises ability to give truly informed consent.
Patients who are moribund or who have concurrent hepatic, renal, cardiac disease.
Contacts and Locations More Information
| Study ID Numbers: | 020227, 02-H-0227 |
| Study First Received: | June 14, 2002 |
| Last Updated: | March 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00039923 History of Changes |
| Health Authority: | United States: Federal Government |
|
Hemolysis CD55 CD59 |
Transfusion Paroxysmal Nocturnal Hemoglobinuria PNH |
|
Urination Disorders Hematologic Diseases Myelodysplastic Syndromes Marchiafava-Micheli Disease Anemia Anemia, Hemolytic Hemoglobinuria Signs and Symptoms |
Proteinuria Preleukemia Paroxysmal Nocturnal Hemoglobinuria Urologic Diseases Hemoglobinuria, Paroxysmal Hemolysis Bone Marrow Diseases |
|
Signs and Symptoms Urological Manifestations Hemoglobinuria Proteinuria Urologic Diseases Hematologic Diseases |
Urination Disorders Myelodysplastic Syndromes Anemia Hemoglobinuria, Paroxysmal Anemia, Hemolytic Bone Marrow Diseases |
